stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
Edgewise Therapeutics, Inc. (EWTX) EBITDA
Edgewise Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$196.8M, compared with −$169.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$221.9M. Over the past ten years it has ranged from −$196.8M (fiscal 2025) to −$17.0M (fiscal 2020) — the current reading is the lowest in ten years. EBITDA has fallen for 5 consecutive fiscal years. Edgewise Therapeutics, Inc. ranks 525th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$196.8M | — |
| FY2024 | −$169.1M | — |
| FY2023 | −$122.1M | — |
| FY2022 | −$71.7M | — |
| FY2021 | −$42.9M | — |
| FY2020 | −$17.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$48.3M | — |
| Jun 2026 | −$62.2M | — |
| Mar 2026 | −$54.5M | — |
| Dec 2025 | −$56.9M | — |
| 23 more quarters | Free account |
Against its own ten years
Low −$196.8M
High −$17.0M
Ten-year median
−$96.9M
Current reading's percentile
17
EBITDA against peers
| Company | EBITDA |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $36.9M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$19.0M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| ABCL AbCellera Biologics Inc. compare | −$192.6M |
| EWTX Edgewise Therapeutics, Inc. | −$221.9M |
| DFTX Definium Therapeutics, Inc. compare | −$227.7M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
| XENE Xenon Pharmaceuticals Inc. compare | −$439.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item